<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Previous studies have provided evidence that, in the early hours of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, a <z:chebi fb="2" ids="8069">luminal</z:chebi> membrane blood-brain barrier (<z:chebi fb="2" ids="33602">BBB</z:chebi>) Na-K-Cl cotransporter (NKCC) participates in <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0002181'>cerebral edema</z:hpo> formation </plain></SENT>
<SENT sid="1" pm="."><plain>Inhibition of <z:chebi fb="2" ids="33602">BBB</z:chebi> NKCC activity by intravenous bumetanide significantly reduces <z:hpo ids='HP_0000969'>edema</z:hpo> and <z:mpath ids='MPATH_124'>infarct</z:mpath> in the rat permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> model of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We demonstrated previously that the <z:chebi fb="2" ids="33602">BBB</z:chebi> cotransporter is stimulated by <z:mp ids='MP_0005039'>hypoxia</z:mp>, aglycemia, and AVP, factors present during <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>However, the underlying mechanisms have not been known </plain></SENT>
<SENT sid="4" pm="."><plain>Ischemic conditions have been shown to activate p38 and JNK MAP kinases (MAPKs) in brain, and the p38 and JNK inhibitors SB-239063 and SP-600125, respectively, have been found to reduce brain damage following middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> and <z:hpo ids='HP_0002138'>subarachnoid hemorrhage</z:hpo>, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>The present study was conducted to determine whether one or both of these MAPKs participates in ischemic factor stimulation of <z:chebi fb="2" ids="33602">BBB</z:chebi> NKCC activity </plain></SENT>
<SENT sid="6" pm="."><plain>Cultured cerebral microvascular endothelial cell NKCC activity was evaluated as bumetanide-sensitive (86)Rb influx </plain></SENT>
<SENT sid="7" pm="."><plain>Activities of p38 and JNK were assessed by Western blot and immunofluorescence methods using antibodies that detect total vs. phosphorylated (activated) p38 or JNK </plain></SENT>
<SENT sid="8" pm="."><plain>We report that p38 and JNK are present in cultured cerebral microvascular endothelial cells and in <z:chebi fb="2" ids="33602">BBB</z:chebi> endothelial cells in situ and that <z:mp ids='MP_0005039'>hypoxia</z:mp> (7% <z:chebi fb="0" ids="15379">O(2)</z:chebi> and 2% <z:chebi fb="0" ids="15379">O(2)</z:chebi>), aglycemia, AVP, and <z:chebi fb="0" ids="15379">O(2)</z:chebi>-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (5- to 120-min exposures) <z:hpo ids='HP_0000001'>all</z:hpo> rapidly activate p38 and JNK in the cells </plain></SENT>
<SENT sid="9" pm="."><plain>We also provide evidence that SB-239063 and SP-600125 reduce or abolish ischemic factor stimulation of <z:chebi fb="2" ids="33602">BBB</z:chebi> NKCC activity </plain></SENT>
<SENT sid="10" pm="."><plain>These findings support the hypothesis that ischemic factor stimulation of the <z:chebi fb="2" ids="33602">BBB</z:chebi> NKCC involves activation of p38 and JNK MAPKs </plain></SENT>
</text></document>